(-)-Reboxetine inhibits muscle nicotinic acetylcholine receptors by interacting with luminal and non-luminal sites.
Neurochem Int
; 63(5): 423-31, 2013 Nov.
Article
en En
| MEDLINE
| ID: mdl-23917086
Palabras clave
(−)-R,R-([2-[α[2-ethoxyphenoxy]benzyl]-morpholine); (−)-reboxetine; AChR; Antidepressants; BS; CCh; Conformational states; DMEM; EC(50); FBS; Hill coefficient; IC(50); K(i); NCA; NSRI; Nicotinic acetylcholine receptors; Norepinephrine selective reuptake inhibitor; PCP; RMSD; RT; Reboxetine; TCAs; [(3)H]TCP; binding saline; carbamylcholine; dulbecco's modified eagle medium; fetal bovine serum; inhibition constant; ligand concentration that inhibits 50% binding or ion flux; ligand concentration that produces 50% increase of binding; n(H); nicotinic acetylcholine receptor; non-competitive antagonist; norepinephrine selective reuptake inhibitor; phencyclidine; piperidyl-3, 4-3H(N)]-(N-(1-(2 thienyl)cyclohexyl)-3, 4-piperidine; room temperature; root mean square deviation; tricyclic antidepressants; α-BTx; α-bungarotoxin
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Morfolinas
/
Receptores Nicotínicos
/
Músculo Esquelético
/
Inhibidores de Captación Adrenérgica
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Neurochem Int
Año:
2013
Tipo del documento:
Article
Pais de publicación:
Reino Unido